Adaptive design trials raise important issues regarding processes for review of interim data and implementation of adaptation decisions, while avoiding bias and maintaining inter-pretability of trial results. We discuss the issues, distinctions versus more familiar monitoring situations, various aspects of operational models for data monitoring, and types of adaptations that may be more or less prone to concerns about bias.
US Food and Drug Administration.Guidance for Clinical Trial Sponsors on the Establishment and Operation of Clinical Trial Data Monitoring Committees.Rockville, MD: US Food and Drug Administration; 2006.
2.
Committee for Medicinal Products for Human Use.Guideline on Data Monitoring Committees.London: European Medicines Agency; 2005.
3.
International Conference on Harmonisation Expert Working Group.ICH harmonised tripartite guideline: statistical principles for clinical trials. 63Federal Register49,583–49,598 (1998).
4.
EllenbergS.S., FlemingT.R., DeMetsD.L.Data Monitoring Committees in Clinical Trials: A Practical Perspective.Chichester, UK: Wiley; 2002.
5.
Committee for Medicinal Products for Human Use.Reflection Paper on Methodological Issues in Confirmatory Clinical Trials With Flexible Design and Analysis Plans.Draft. London: European Medicines Agency; 2006.
6.
MacaJ., BhattacharyaS., DragalinV., GalloP., KramsM.Adaptive seamless phase II/III designs: background, operational aspects, and examples. Drug Inf J.2006; 40: 463–473.
7.
WhiteheadJ.The Design and Analysis of Sequential Clinical Trials.Chichester, UK: Wiley; 1997.
8.
Chuang-SteinC., AndersonK., GalloP., CollinsS.Sample size re-estimation: a review and recommendations. Drug Inf J.2006; 40: 475–484.
